Serum TNF-alpha levels correlate with disease severity and are reduced by effective therapy in plaque-type psoriasis

Journal of Biological Regulators and Homeostatic Agents

Volumn 11, Issue 3, 1997, Pages 115-118

  Mussi, A ^a   Bonifati, C ^a   Carducci, M ^a   D'Agosto, G ^a   Pimpinelli, F ^a   D'Urso, D ^a   D'Auria, L ^a   Fazio, M ^a   Ameglio, F ^a  

^a SAN GALLICANO DERMATOLOGICAL INSTITUTE   (Italy)

Author keywords

PASI score; Psoriasis; sE selectin; Serum; TNF alpha

Indexed keywords

CYCLOSPORIN A; CYTOKINE; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; ETRETINATE; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PSORIASIS;

EID: 0031469174     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Nickoloff BJ. The cytokine network in psoriasis. Arch Dermatol 1991; 127: 871-84.
2. Grossman RM, Krueger J, Yourish D. Interleukin-6 is expressed in high levels in psoriatic skin and stimulates proliferation of cultured human keratinocytes. Proc Nat Acad Sci USA 1989; 86: 6367-71.
3. Bonifati C, Carducci M, Cordiali Fei P, et al. Correlated increases of tumor necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients. Relationships with disease severity. Clin Exp Dermatol 1994; 19: 383-7
4. Murloch M, Navaseria H, Balkwell F, Trousdale J, Leigh I. Tumor necrosis factor and psoriasi. Br J Dermatol 1989; 119 (S33): 46.
5. Loetsher H, Steinmetz M, Lesslauer W. Tumor necrosis factor, receptors and inhibitors. Cancer Cells (Review) 1991; 3: 221-32.
6. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. Science 1985; 229: 869.
7. Schindler R, Mancilla J, Ghorbani R, Clark C, Dinarello CA. Correlations and interactions in the production of interleukin-6 (IL-6), interleukin-1 (L-1) and tumour necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood 1990; 75-40.
8. Olsson I, Gatanaga T, Gullberg U, Lantz M, Granger GA. Tumur necrosis factor (TNF), binding proteins (soluble TNF receptor forms) with possible roles in inflammation and malignancy. Eur Cytokine Netw 1993; 4: 169-80.
9. Tracey KJ, Cerami A. Tumor necrosis factor: a pleiotropic cytokine and therapeutic target. Ann Rev Med (Review) 1994; 45: 491-513.
10. Beutler B, Cerami A. The biology of cachectin/TNF - a primary mediator of the host response. Annu Rev Immunol 1989; 7: 625-55.
11. Spiegelman BM, Hotamisligil GS. Through thick and thin: wasting, obesity and TNF-alpha. Cell (Review) 1993; 73: 625-38.
12. Fredrikson T, Patterson V. Severe psoriasis oral therapy with a new retinoid. Dermatologica 1978; 157: 238-44.
13. Snedecor GW, Cochran WG. Statistical methods. The Iowa State University Press, Ames, Iowa, Usa 1969.
14. Nickoloff BJ, Karabin GD, Barker JNW. Cellular localization of interleukin-8 and its inducer, tumour necrosis factor-alpha in psoriasis. Am J Pathol 1991, 138: 129-40.
15. Ameglio F, Bonifati C, Pietravalle M, Fazio M. Interleukin-6 and tumour necrosis factor levels decrease in the suction blister fluids of psoriatic patients during effective therapy. Dermatology 1994; 189: 59-63.
16. Gomi T, Shiohara T, Munakata T, Imanishi K, Nagashima M. Interleukin-1 -alpha, tumour necrosis factor-alpha and interferon-gamma in psoriasis. Arch Dermatol 1991; 127: 827-30.
17. Sagawa Y, Shiohara T, Imanishi K, Nagashima M. Is sustained production of tumour necrosis factor-alpha relevant to the development of pustular psoriasis? Dermatology 1993; 187: 81-3.
18. Bonifati C, Trento E, Carducci M, et al. Soluble E-selectin and soluble tumour necrosis factor receptor (60kD) serum levels in patients with psoriasis. Dermatology 1995; 190: 128-31.
19. Carducci M, Mussi A, Bonifati C, et al. Correlation of lesional skin corneometry values with serum E-selectin levels and disease severity in patients affected by plaque-type psoriasis: recovery after effective therapy. J Dermatol 1995; 22: 475-9.
20. Mussi A, Carducci F, Bonifati C, Pittarello A, Fazio M, Ameglio F. Are soluble membrane molecules reliable early markers for monitoring psoriasis? G Ital Dermatol Venereol 1995; 130: 73-5.
21. Carducci M, Mussi A, Bonifati C, Pittarello A, Fazio M, Ameglio F. sIL-2R, sICAM-1 and Beta-2 microglobulin serum levels are not modified after one month of cyclosporine A therpay in severe psoriasis. Life Chem Reports 1996; 14: 229-32.
22. Kowalzick L, Bildau H, Neubar K, Koehler I, Ring J. Clinical improvement in psoriasis during dithranol/UVB therapy does not correspond with a decrease in elevated serum soluble ICAM-1 levels. Arch Dermatol Res 1993; 285: 233-5